{"pub": "reuters", "url": "https://reuters.com/article/us-lilly-results/eli-lilly-reports-9-rise-in-third-quarter-profit-idUSKBN1X21A4", "downloaded_at": "2019-10-23 10:55:54.662020+00:00", "title": "Eli Lilly reports 9% rise in third-quarter profit", "language": "en", "text": "FILE PHOTO: The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 18, 2018. REUTERS/Brendan McDermid\n\n(Reuters) - Eli Lilly and Co (LLY.N) reported a 9.1% increase in third-quarter profit on Wednesday, helped by higher sales of its top-selling diabetes drug, Trulicity, and lower tax expense.\n\nNet income rose to $1.25 billion, or $1.37 per share, in the quarter ended Sept. 30, from $1.15 billion, or $1.12 per share, a year earlier.\n\nRevenue rose 3.2% to $5.48 billion.", "description": "Eli Lilly and Co reported a 9.1% increase in third-quarter profit on Wednesday, helped by higher sales of its top-selling diabetes drug, Trulicity, and lower tax expense.", "authors": ["Reuters Editorial", "Min Read"], "top_image": "https://s2.reutersmedia.net/resources/r/?m=02&d=20191023&t=2&i=1444070907&w=1200&r=LYNXMPEF9M0TD", "published_at": "2019-10-23"}